BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TUB-030 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TUB-030\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06657222-2784@assetmemo.bio
DTSTAMP:20261121T005734Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:TUB-030: Phase 1/2 readout est. (NCT06657222)
DESCRIPTION:TUB-030\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: First
  in Human Study of TUB-030 in Patients With Advanced Solid Tumors\nEstimat
 ed primary completion: December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tub-030#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06657222
URL:https://assetmemo.bio/drug/tub-030#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
